Biovica continouse to increase 12m rolling IVD test sales in Q3 of SEK 0.74m (650% rolling 12m) and total sales of SEK 2.3m after adding ROU sales (test and services). Biovica has also doubled Pharma service orders to SEK 25m and expanded the US market reach significantly lately. This progress is also much needed considering that Biovica is still far off breakeven sales levels.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/